Premium
Molecular staging of surgical margins after radical prostatectomy by detection of telomerase activity
Author(s) -
Straub Bernd,
Müller Markus,
Krause Hans,
Goessl Carsten,
Schrader Mark,
Heicappell Rüdiger,
Miller Kurt
Publication year - 2001
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.1128
Subject(s) - prostatectomy , telomerase , medicine , prostate cancer , stage (stratigraphy) , urology , prostate , carcinoma , cancer , surgery , oncology , pathology , biology , gene , paleontology , biochemistry
Background The further course of prostate cancer (PC) after radical prostatectomy (RPX) is decisively influenced by the local tumor stage. Although it is thus far possible to assess the risk of local recurrence from the pathohistology, precise predictions cannot be made. A more precise evaluation would be desirable, mainly for early planning of adjuvant therapy. Other authors have shown that telomerase activity may be a marker for malignant potential. We assessed the detection of telomerase activity using the telomeric repeat amplification protocol (TRAP) in surgical margins compared to conventional histopathological examination. Methods Ninety‐two patients with local PC who underwent RPX were examined. After RPX biopsies were obtained from four defined areas of the prostatic fossa and processed by TRAP assay for telomerase activity using a standard protocol. Results In 5 of 48 patients (10.4%) with organ‐confined prostate carcinoma (pT2) telomerase activity could be detected. Seven of 47 patients (14.9%) with locally advanced PC (> pT2) had at least one positive specimen. Conclusions The results obtained in our study indicate that detection of telomerase activity by TRAP assay may be a suitable parameter for molecular staging of surgical margins, because of the high tumor‐specificity. Further follow‐up must clarify whether patients with positive molecular detection have an increased risk of local recurrence. Prostate 49:140–144, 2001. © 2001 Wiley‐Liss, Inc.